What is EVMN's market cap?

$219.20M, based on the Nov 4 close of $6.04.

Does Evommune pay a dividend?

No regular cash dividend has been paid in the last year.

How much of EVMN is sold short?

3.5M shares, 15.4% of float, as of Oct 15, 2026.

What sector is EVMN in?

Healthcare, in the Pharmaceuticals industry.

NYSE · EVMNHealthcarePharmaceuticals

Evommune, Inc. (EVMN)

$6.04+1.68%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$5.88▼ 70.91% in range

Nov 6, 2025Low $5.10 · High $31.57Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Evommune closed at $6.04 on Nov 4, up 1.68%, 80.9% below its 52-week closing high. Volume of 352.2K shares was 0.37× its 20-day average (below normal).

Split-adjusted performance: -8.6% over one month, -74.7% over six months.

Short interest was 3.5M shares at the Oct 15 settlement, up 22.1% from the prior report (15.4% of float, 3.4 days to cover).

Market cap$219.2M36.3M shares

Revenue · quarter$0.00—

Diluted EPS$-0.89—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range5.10 – 31.57−80.9% from high

Volume352.2K0.37× 20-day avg

Volatility · 60d87.2%Annualised

Short % of float15.4%3.4 days to cover

Net cash$200.4MCash $200.8M

Next earnings—Not scheduled

Split-adjusted performance

1W −4.3%1M −8.6%3M −54.9%6M −74.7%YTD −64.7%1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum10

Revenue growth—

Net margin—

Value (low P/E)—

Size49

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short3.5M+22.1% vs prior

Days to cover3.4Settled Oct 15

% of float15.4%

Short vol. 10d47.9%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
EVMNEvommune	$6.04	+1.68%	−74.7%	—	—	—	$219.2M
ELDNEledon Pharmaceuticals	$2.70	+3.05%	−28.9%	—	—	—	$219.4M	Compare
ADCTADC Therapeutics SA	$1.72	+10.97%	−55.4%	+2.2%	−86.1%	—	$219.6M	Compare
KROSKeros Therapeutics	$10.83	0.00%	−8.1%	−100.0%	—	—	$214.7M	Compare
NATRNature's Sunshine Products	$12.84	+6.38%	−51.1%	+1.9%	3.0%	12.5	$225.9M	Compare
SIGASIGA Technologies	$3.15	+1.29%	−33.0%	−49.5%	30.4%	—	$226.3M	Compare
RNACCartesian Therapeutics	$6.82	+6.40%	−18.2%	−100.0%	—	—	$206.3M	Compare
VNDAVanda Pharmaceuticals	$3.88	+3.47%	−47.8%	+24.1%	−32.3%	—	$234.6M	Compare
CAMPCAMP4 Therapeutics	$3.74	−2.35%	−7.9%	+18.8%	−1884.8%	—	$234.7M	Compare

News about Evommune

All news →

No recent articles focused on Evommune. 1 articles mention it in passing.

Quick answers

What does Evommune do?: Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC).
What is EVMN's market cap?: $219.20M, based on the Nov 4 close of $6.04.
Does Evommune pay a dividend?: No regular cash dividend has been paid in the last year.
How much of EVMN is sold short?: 3.5M shares, 15.4% of float, as of Oct 15, 2026.
What sector is EVMN in?: Healthcare, in the Pharmaceuticals industry.

About Evommune

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

HQ: Palo Alto, CA48 employeesListed Nov 6, 2025evommune.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology